Recently, it has been shown that persistence of leukemic HSCs in bone marrow of patients with CML requires the inhibition of the PP2A and BCR–ABL1 expression but not its activity (27). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.